Autoantibody fine specificity restriction is associated with clinical response in RA treated with abatacept and methotrexate. Journal Abstract - Guideline Central

Autoantibody fine specificity restriction is associated with clinical response in RA treated with abatacept and methotrexate.

Published: 2026 Jan

Authors

, , , , , , , , , , ,

Abstract

Anti-modified protein antibodies (AMPA) are central in rheumatoid arthritis (RA). We evaluated whether changes in fine specificities (FS) of anti-citrullinated protein antibodies (ACPA) and anti-CarP antibodies relate to clinical prognosis in RA patients treated with abatacept (ABA) plus methotrexate (MTX).

Keywords: ACPA, Anti-CCP, Anti-CarP, Disease activity, Fine specificities, IgA isotype, Prognosis, Rheumatoid arthritis

Source

Clinical immunology (Orlando, Fla.)

Publication Type

Journal Article

Language

English

PubMed ID

41130331

MeSH terms

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.